StephenLeongMD

Gastrointestinal Cancer

Associate Professor, School of Medicine, University of Colorado; Director, Developmental Therapeutic Clinical (Phase I) Program

Join to view full profile

Dr. Leong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Leong's full profile

Already have an account?

Office
12605 E 16th Ave
Aurora, CO 80045
Phone+1 720-848-0000

Summary

Dr. Stephen Leong is a medical oncologist at the University of Colorado Cancer Center. He received his medical degree from Royal College of Surgeons Ireland and did his medical oncology fellowship at University of Colorado. He specializes in gastrointestinal cancer, adrenal cancer and developmental therapeutics.

Education & Training

Harvard Medical SchoolCertificate in Palliative Care Education and Practice, Palliative Care, 2011 - 2011
University of ColoradoFellowship, Hematology and Medical Oncology, 2004 - 2007
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2000 - 2003
University College DublinMMedScience, Physiology, 1998 - 1999
Royal College of Surgeons IrelandClass of 1997

Certifications & Licensure

CO State Medical License 2007 - 2023
PA State Medical License 2000 - 2004

Awards, Honors, & Recognition

Nominated for Golden Stethoscope "Best Role Model" University of Colorado School of Medicine, 2016
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Scholarship, Program in Palliative Care Education and Practice Harvard Medical School, 2011
Paul Calabresi Clinical Oncology Scholar Award (K12 Award) National Cancer Institute, 2009
Developmental Therapeutics Poster Award University of Colorado, 2007
Scholarship American Society of Clinical Oncology (ASCO)/American Association for Cancer Research (AACR), 2006
Institutional Ruth L. Kirschstein National Research Service Award NIH, 2005
Second Class Honors Grade 2: Physiology, Microbiology and Chemistry Royal College of Surgeons, 1991
Second Class Honors Grade 1 Royal College of Surgeons, 1991
First Class Honors in General Practice Royal College of Surgeons, 1991
Government of Canadian Scholarship University of Western Ontario, 1989
Silver Medal Lieutenant Governor General of Ontario, 1988
Join now to see all

Clinical Trials

Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Start of enrollment: 2007 Oct 01
Completed
Phase 1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
OSI-906 and Irinotecan in Patients With Advanced Cancer Start of enrollment: 2009 Dec 01
Terminated
Phase 1
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations Start of enrollment: 2014 Jan 07
Completed
Phase 2
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Start of enrollment: 2016 Mar 08
Active, not recruiting
Phase 1, Phase 2
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2016 Apr 06
Active, not recruiting
Phase 2
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Start of enrollment: 2016 Jun 01
Terminated
Phase 1
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread Start of enrollment: 2016 Jun 17
Completed
Phase 1, Phase 2
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Start of enrollment: 2016 Nov 29
Completed
Phase 2
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Start of enrollment: 2017 Feb 16
Active, not recruiting
Phase 1, Phase 2
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors Start of enrollment: 2017 Aug 08
Completed
Phase 1, Phase 2
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer Start of enrollment: 2017 Dec 19
Completed
Phase 2
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Start of enrollment: 2019 Oct 31
Recruiting
Phase 2
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Start of enrollment: 2019 Sep 06
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

918 citations
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler, Aik Choon Tan, Colin D. Weekes, Antonio Jimeno, Stephen Leong
Nature Reviews. Clinical Oncology. 2012-06-01
155 citations
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
Razelle Kurzrock, Amita Patnaik, Joseph Aisner, Terri Warren, Stephen Leong
Clinical Cancer Research. 2010-04-15
39 citations
Development of new preclinical models to advance adrenocortical carcinoma research.
Katja Kiseljak-Vassiliades, Yu Zhang, Stacey M. Bagby, Adwitiya Kar, Nikita Pozdeyev
Endocrine-Related Cancer. 2018-01-25

Books/Book Chapters

Principles of Anticancer Drug Development
Chapter: Phase I Clinical Trials of Anticancer Agents.
Leong S, Call J, Ajeit AA, Messersmith WAEditors: Hidalgo, M; Garrett-Mayer, E; Clendeninn, N. and Eckhardt SG.Springer Science2011
Principles of Molecular Diagnostics and Personalized Cancer Medicine
Chapter: Approaches to Integration of Personalized Medicine in Early Cancer Drug Development.
Page 659 - 673Tan AC, Leong S, Pitts TM, Tentler JJ, Eckhardt SGEditors: Dongfeng Tan and Henry Lynch.Lippincott Williams & Wilkins

Abstracts/Posters

Prognostic factors for 90-day mortality in patients with solid malignancies treated on Phase 1 trials sponsored by the Cancer Therapy Evaluation Program (CTEP) of the ...
Wong KM, Rubinstein L, Rinker M, Smith GL, Sharon E, Eckhardt SE, Messersmith WA, Leong S, Harris PJ, Gao D, ASCO General Meeting, 1/1/2016
Predicting outcomes in patients with advanced malignancies treated on Phase 1 clinical trials.
Wong KM, Gao D, McCoy H, Brock A, Powell RW, O'Bryant CL, Camidge DR, Gore L, Jimeno A, Diamond JR, Messersmith WA, Eckhardt SG, Leong S, J Clin Oncol, 1/1/2015
Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6+bevacizumab in patients with advanced solid tumors and colorecta...
Rosen LS, Goldman J, Stewart S, Hubbard JM, Roos M, Capdevila J, Maynes L, Lin W, O'Keeffe B, Lackner M, Spoerke J, Ware J, Arnieri B, Freas E, Leong S, 26th EORTC-NCI-AACR Symposium, Barcelona, Spain, 1/1/2014
A Phase 1B Study to Evaluate the Safety and Pharmacology of the Dual PI3K-MTOR Inhibitor GDC-0980 in Combination with a Fluoropyrimidine, Oxaliplatin, and Bevacizumab ...
Rosen LS, Goldman J, Stewart S, Hubbard JM, Roos M, Lin W, Shankar G, Capdevila J, Freas E, Leong S, European Society of Medical Oncology (ESMO) Congress, Vienna, Austria, 1/1/2012
Assessment of the combination of PF-04691502 (PI3K/mTORi) and PD-0325901 (MEKi) against colorectal cell lines and patient-derived xenograft models.
Newton TP, Pitts TM, Addison RM, Bagby SM, McPhillips K, Selby HM, Eckhardt SG, Leong S, 24th EORTCNCI-AACR Symposium, Dublin Ireland, 1/1/2012
Molecular Markers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Human Colorectal Cancer (CRC) models.
Tentler JJ, Bagby SM, Tan AC, Pitts TM, Selby HM, McPhillips KL, Eckhardt SG, Leong S, 24th EORTC-NCI-AACR Symposium, Dublin, Ireland, 1/1/2012
Preclinical antitumor efficacy of the combination of the IGF-1R/IR dual kinase inhibitor, OSI-906, with the MEK inhibitor, selumetinib, against colorectal cancer cell ...
Newton TP, Pitts TM, Flanigan SA, McManus MC, Spreafico A, Arcaroli J, Eckhardt SG, Leong S, AACR/NCI/EORTC International Conference in Molecular Targets and Cancer Therapeutics, San Francisco, CA, 1/1/2011
Join now to see all

Press Mentions

Oncologists See Benefit of Medical Marijuana, but Not Comfortable PrescribingMay 30th, 2019
Suny Downstate Hematology Oncology FellowshipApril 3rd, 2021